Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
  Home Print this page Email this page Small font sizeDefault font sizeIncrease font size Users Online: 104  

    Article Cited by others

ORIGINAL ARTICLE

Labeling and Biological Evaluation of 99m Tc-HYNIC-Trastuzumab as a Potential Radiopharmaceutical for In Vivo Evaluation of HER2 Expression in Breast Cancer

Calzada Victoria, Garcia Fernanda, Fernández Marcelo, Porcal Williams, Quinn Thomas, Alonso Omar, Gambini Juan Pablo, Cabral Pablo

Year : 2013| Volume: 12| Issue : 1 | Page no: 27-32

   This article has been cited by
 
1 Development of Lu-177-trastuzumab for radioimmunotherapy of HER2 expressing breast cancer and its feasibility assessment in breast cancer patients
Priya Bhusari,Rakhee Vatsa,Gurpreet Singh,Madan Parmar,Amanjit Bal,Devinder K. Dhawan,Bhagwant R. Mittal,Jaya Shukla
International Journal of Cancer. 2017; 140(4): 938
[Pubmed]  [Google Scholar] [DOI]
2 Development and characterization of DTPA-trastuzumab conjugates for radiolabeling with Tc-99m: A radiopharmaceutical for HER2/neu breast cancer
Priya Bhusari,Rakhee Vatsa,Gurpreet Singh,Devinder K. Dhawan,Jaya Shukla,Bhagwant R. Mittal
Journal of Drug Delivery Science and Technology. 2015; 29: 8
[Pubmed]  [Google Scholar] [DOI]
3 Synthesis, physicochemical and biological evaluation of technetium-99m labeled lapatinib as a novel potential tumor imaging agent of Her-2 positive breast cancer
Ewa Gniazdowska,Przemyslaw Kozminski,Krzysztof Bankowski,Wojciech Luniewski,Leszek Królicki
European Journal of Medicinal Chemistry. 2014; 87: 493
[Pubmed]  [Google Scholar] [DOI]

 

Read this article